<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, June 29, 2018 (HealthDay News) — A visible fluorescent injectate (VFI)-based approach for direct measurement of glomerular filtration rate (mGFR) is accurate with high reproducibility, according to a study published in the June issue of the Journal of the American Society of Nephrology<\/i>.<\/p>\n
Dana V. Rizk, M.D., from the University of Alabama at Birmingham, and colleagues developed a new biomarker, VFI, consisting of a 150-kD rhodamine derivative and 5-kD fluorescein carboxymethylated dextrans. VFI-based mGFR values were compared with values obtained by measuring iohexol plasma disappearance in a study involving 16 adults with normal kidney function, eight with chronic kidney disease (CKD) stage 3, and eight with CKD stage 4. VFI-based mGFR required three blood draws over three hours, while five samples taken over six hours were required for iohexol-based mGFR. Repeat VFI injections at 24 hours were received by eight healthy participants.<\/p>\n
The researchers found that in all participants, there were close linear correlations for VFI-based mGFR values with the iohexol-based mGFR values. The injections were tolerated well, even when they were given on consecutive days. There were no reports of serious adverse events. There was high reproducibility for VFI-based mGFR.<\/p>\n
“The VFI-based approach allows for the rapid determination of mGFR at the bedside while maintaining patient safety and measurement accuracy and reproducibility,” the authors write.<\/p>\n
Several authors disclosed ties to FAST Biomedical; one author disclosed ties to TdB Consultancy, which collaborates with FAST BioMedical on dextran development. One author was employed by ICON Early Phase Services LLC.<\/p>\n
Abstract<\/a><\/p>\n Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n